NNNN - CIK 0001982708
No parsed quarterly data available for Anbio Biotechnology yet.
Anbio Biotechnology reported operating cash flow of -$6.74M for fiscal year 2025. That is down 423.9% from $2.08M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.